查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016208

放射腫瘤市場：按技術、組件、給藥方法、應用和最終用戶分類－2026-2032年全球市場預測

Radiation Oncology Market by Technology, Component, Delivery Mode, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，放射腫瘤學市場價值將達到 153.4 億美元，到 2026 年將成長至 163.9 億美元，到 2032 年將達到 281.3 億美元，複合年成長率為 9.04%。

主要市場統計數據
基準年 2025 153.4億美元
預計年份：2026年 163.9億美元
預測年份 2032 281.3億美元
複合年成長率 (%) 9.04%

對現代放射腫瘤學趨勢的權威分析，重點在於臨床創新、營運韌性和跨專業合作。

放射腫瘤學正處於快速技術創新和不斷演進的醫療服務模式的交匯點，臨床療效、病患體驗和營運效率成為首要關注點。精準照射、影像融合和治療計劃軟體的進步正在改變臨床醫生對治療耐受性和器官保護的思考方式，從而促成​​了針對不同腫瘤類型製定更精細的治療方案。同時，醫療機構面臨複雜的採購週期，以及越來越大的壓力，需要用可證實的臨床效益和營運韌性來證明資本投資的合理性。

詳細檢視精準放射治療平台、軟體智慧和醫療分散化如何重塑臨床實務和運作模式。

放射腫瘤學領域經歷了變革性的轉變，這得益於精準放射治療技術、軟體智慧和新型醫療環境的融合。強度調節放射治療、容積放射治療技術和立體定位放射治療的創新提高了在限制正常組織受照劑量的同時增加腫瘤劑量的能力，從而影響了治療方案和轉診模式。同時，質子治療的成熟和筆射束掃描技術的改進，也拓展了關於哪些適應症需要降低累積劑量的臨床討論。

貿易政策的變化如何影響放射治療整個基礎設施和服務的採購彈性、供應連續性和部署計畫？

近期針對進口醫療設備及零件的關稅措施，正在採購、服務交付和供應鏈策略等各領域產生一系列累積影響。針對專用放射治療硬體及子組件的關稅上調，推高了設備密集型平台的採購成本，並可能因供應商和買家重新評估採購方案而延長採購週期。這些壓力促使醫療系統和供應商重新審視供應商合約、庫存政策以及本地組裝和區域採購的可行性，以降低貿易政策變化的風險。

全面概述技術、組件、交付方式、應用程式和最終用戶等相互關聯的部分如何決定部署路徑和營運複雜性。

對細分市場的詳細分析揭示了技術平台、組件類型、照射模式、臨床適應症和終端用戶環境如何相互作用，從而影響部署和運行需求。從技術角度來看，近距離放射仍以高劑量率 (HDR) 和低劑量率 (LDR) 方法為區分標準，以應對不同的臨床場景和工作流程需求。同時，強度調變技術分為「步進式」方法和容積旋轉調強放射治療 (VMAT)，每種方法的效率和計畫複雜性各不相同。質子治療分為兩種模式：被動散射和筆射束掃描，每種模式對設施設計和治療計畫的影響各不相同。立體定位放射治療可透過專用機器人系統或基於直線加速器的平台進行，具體取決於病灶類型和設施能力。

對影響放射治療在全球推廣的基礎設施發展、報銷制度和策略重點方面的區域差異進行深入分析。

區域趨勢持續影響醫療服務提供者和供應商的技術採納、報銷環境和策略重點。美洲的需求促進因素多種多樣，一些系統優先考慮先進的高精度治療，而另一些系統則專注於透過分散的醫療機構擴大服務覆蓋範圍。各國和地方政府的法規結構和報銷途徑各不相同，進而影響著採購計畫和服務模式。歐洲和中東及非洲（EMEA）市場的基礎設施成熟度參差不齊，一些地區的監管協調正在推進，而另一些地區仍然存在能力限制。因此，需要合作模式和跨境培訓舉措來加速能力建構。

因此，供應商和提供者需要投資於培訓和支援系統，以促進永續部署和品質保證，同時調整打入市場策略，以適應當地的法規環境、基礎設施發展和臨床實踐規範。

放射腫瘤公司面臨的主要競爭行動和策略挑戰，重點在於整合解決方案、臨床合作和服務主導的差異化。

放射腫瘤領域的企業行為以策略性的產品組合定位、彌合臨床與營運差距的夥伴關係以及對延長設備生命週期的服務模式的投資為特徵。主要企業和技術供應商強調將放射治療平台與計劃和品質保證軟體相結合的整合解決方案，而專業的治療設備供應商則專注於粒子束治療和立體定位放射治療機器人等特定細分領域。同時，專業的服務機構和第三方維護公司對於確保運作和提供培訓至關重要，尤其是在複雜的安裝環境和多站點網路中。

為了加速永續部署，領導者需要採取切實可行的策略措施，以協調臨床證據、供應彈性和可擴展的服務模式。

產業領導者應採取多管齊下的方法，將臨床證據、供應鏈韌性和營運規模化相結合。首先，優先投資於臨床檢驗計畫和多學科臨床試驗，以證明產品在特定適應症方面的比較優勢，從而增強產品核准的臨床證據，並促進與支付者的談判。其次，透過區域夥伴關係和雙重採購協議實現供應鏈多元化，並制定庫存策略以降低貿易政策波動和物流中斷帶來的風險。

為了確保實際相關性，有必要對整合臨床檢驗、營運觀察和政策分析的混合方法研究途徑進行透明的解釋。

本研究採用綜合分析方法，結合一手質性資料和嚴謹的二手分析，確保研究結果基於臨床實務和實際操作情況。主要調查方法包括對臨床負責人、醫學物理學家和採購主管進行結構化訪談，並輔以實地考察和對不同治療環境的工作流程進行直接觀察。這些工作有助於深入了解實際的排班限制、人員配備模式以及新型治療技術對營運的影響。

一份簡潔、全面的分析報告，重點闡述了決定永續採用的臨床創新、營運結構發展和政策韌性等因素的融合。

這項分析強調，放射腫瘤學正沿著幾個相互融合的方向發展：精準放射技術、先進的軟體生態系統、分散式醫療環境以及加強的供應鏈監管。這些趨勢在為改善臨床療效帶來機會的同時，也帶來了應對營運複雜性的挑戰，需要透過實證實踐、人才培養和穩健的採購慣例來實現。因此，臨床團隊和管理人員必須採取綜合策略，將技術應用與完善的培訓和服務模式相結合，以在各種環境下維持高品質的醫療服務。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：放射腫瘤市場：依技術分類

  • 近距離放射治療
    • 高劑量率
    • 低劑量率
  • 強度調控放射治療
    • 步進式 IMRT
    • 容積調節弓治療
  • 質子束療法
    • 被動散射
    • 筆射束掃描
  • 立體定位放射治療
    • 電腦刀
    • 直線加速器底座
  • 3D自適應放射治療

第9章：放射腫瘤市場：依組成部分分類

  • 硬體
  • 服務
  • 軟體

第10章：放射腫瘤市場：依給藥方式分類

  • 外部輻射
    • 旋轉樑
    • 固定樑
  • 手術過程中
    • 微創
    • 開放性手術

第11章：放射腫瘤市場：依應用領域分類

  • 乳癌
  • 頭頸癌
  • 肺癌
  • 攝護腺癌

第12章：放射腫瘤市場：依最終用戶分類

  • 門診手術中心
    • 獨立的
    • 醫院附屬機構
  • 癌症治療中心
    • 多專科醫療
    • 獨立型
  • 醫院
    • 私人的
    • 民眾

第13章：放射腫瘤市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：放射腫瘤市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：放射腫瘤市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國放射腫瘤市場

第17章：中國放射腫瘤市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accuray Incorporated
  • Bayer AG
  • Best Medical International, Inc.
  • Canon Medical Systems Corporation
  • Elekta AB
  • Hitachi, Ltd.
  • Ion Beam Applications SA
  • Isoray, Inc.
  • Mevion Medical Systems, Inc.
  • Novartis AG
  • Panacea Medical Technologies Pvt. Ltd.
  • RefleXion Medical, Inc.
  • Siemens Healthineers AG
  • Varian Medical Systems, Inc.
  • ViewRay, Inc.
Product Code: MRR-035AB9C0DA6B

The Radiation Oncology Market was valued at USD 15.34 billion in 2025 and is projected to grow to USD 16.39 billion in 2026, with a CAGR of 9.04%, reaching USD 28.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.34 billion
Estimated Year [2026] USD 16.39 billion
Forecast Year [2032] USD 28.13 billion
CAGR (%) 9.04%

An authoritative framing of contemporary radiation oncology dynamics emphasizing clinical innovation, operational resilience, and multidisciplinary alignment

Radiation oncology is at the intersection of rapid technological innovation and shifting care delivery models, where clinical outcomes, patient experience, and operational efficiency converge as primary priorities. Advances in precision delivery, imaging integration, and treatment planning software have changed how clinicians think about therapeutic windows and organ preservation, leading to more nuanced treatment protocols across tumor types. At the same time, providers face complex procurement cycles and growing pressures to justify capital investments with demonstrable clinical benefits and operational resilience.

Consequently, oncology teams, hospital administrators, and technology vendors must align clinical evidence, regulatory compliance, and service support to deliver consistent, high-quality radiation care. This requires multidisciplinary collaboration that spans medical physics, radiation therapy planning, surgical oncology, and diagnostic imaging. Moreover, as treatment pathways evolve to emphasize hypofractionation, stereotactic approaches, and combined modality care, stakeholders must prioritize interoperability and data-driven quality assurance to maintain patient safety and optimize outcomes.

Moving forward, leaders will need to balance innovation adoption with pragmatic operational planning, ensuring training, reimbursement alignment, and supply chain robustness. The introduction of novel delivery platforms and software tools represents both an opportunity to improve patient outcomes and a responsibility to integrate these tools into clinical workflows without disrupting continuity of care

A detailed exploration of how precision delivery platforms, software intelligence, and care decentralization are reshaping clinical practice and operational models

The radiation oncology landscape has undergone transformative shifts driven by convergence of precision delivery technologies, software intelligence, and new care settings. Innovations in intensity modulated delivery, volumetric techniques, and stereotactic approaches have sharpened the ability to escalate tumor dose while limiting exposure to healthy tissue, which in turn has influenced treatment protocols and referral patterns. Simultaneously, the maturation of proton delivery and refinements in pencil beam scanning have expanded the clinical conversation about indications that may benefit from reduced integral dose.

In parallel, software ecosystems now underpin almost every stage of the treatment pathway, from image-guided planning and adaptive workflows to quality assurance and outcomes tracking. Artificial intelligence and automation have begun to streamline contouring and plan optimization, improving throughput and enabling clinicians to focus on complex cases. Delivery models are also shifting as ambulatory surgical centers and specialized cancer centers integrate radiation services that were once concentrated in tertiary hospitals. This decentralization requires robust service models, remote planning capabilities, and standardized training to maintain quality across diverse sites.

Together, these advances create opportunities for improved patient experience and outcome personalization, while also introducing challenges related to interoperability, workforce development, and evidence generation. As stakeholders adapt, strategic investments in clinical validation, cross-disciplinary education, and resilient supply chains will determine which innovations achieve sustained clinical impact

How trade policy shifts are reshaping procurement resilience, supply continuity, and deployment timelines across radiation therapy infrastructure and services

Recent tariff actions affecting imported medical equipment and components have created a set of cumulative effects that ripple across procurement, service delivery, and supply chain strategies. Increased duties on specialized radiotherapy hardware and subcomponents raise acquisition costs for equipment-intensive platforms and may extend procurement timelines as suppliers and buyers reassess sourcing options. These pressures have prompted health systems and vendors to reexamine supplier contracts, inventory policies, and the feasibility of localized assembly or in-region sourcing to mitigate exposure to trade policy volatility.

Beyond direct capital costs, tariffs influence deployment schedules for high-capital systems and can slow the expansion of new clinical capabilities in settings that are financially constrained. Service contracts and spare part logistics face potential delays as cross-border movements of replacement components encounter additional administrative steps. Software and cloud-enabled services are less susceptible to tariffs but still depend on hardware availability and system uptime, which makes integrated service models and remote diagnostics increasingly valuable as buffering mechanisms.

Clinical programs respond by prioritizing resilient procurement frameworks, including dual-sourcing strategies, longer-term parts inventories, and stronger partnerships with regional service providers. Concurrently, policymakers and industry stakeholders are negotiating pathways that balance domestic manufacturing incentives with the need to maintain timely access to specialized technologies. In this context, organizations that proactively adapt contracting, inventory management, and vendor collaboration are better positioned to preserve continuity of care and operational flexibility despite trade-related headwinds

A comprehensive synthesis of how intersecting technology, component, delivery, application, and end-user segments determine adoption pathways and operational complexity

A nuanced reading of segmentation reveals how technology platforms, component types, delivery modes, clinical indications, and end-user settings interact to shape adoption and operational needs. Within technology, brachytherapy remains differentiated by high dose rate and low dose rate approaches that address distinct clinical scenarios and workflow requirements, while intensity modulated techniques split between step and shoot approaches and volumetric modulated arc therapy that offer varying efficiencies and planning complexities. Proton therapy is distinguished by passive scattering and pencil beam scanning modalities, each with implications for facility design and treatment planning, and stereotactic body radiotherapy is delivered through specialized robotic systems or linac-based platforms that cater to different lesion types and institutional competencies.

Components across hardware, services, and software present divergent procurement logics: hardware requires capital planning and facility readiness, services emphasize training and maintenance rhythms, and software centers on integration and data governance. Delivery mode continues to bifurcate between external beam and intraoperative strategies; external beam pathways are further categorized by rotational beam systems that prioritize volumetric delivery and stationary beam systems that emphasize fixed-beam workflows, while intraoperative approaches range from minimally invasive applications to open surgical settings that demand close surgeon-physicist coordination.

Clinical applications such as breast, head and neck, lung, and prostate cancers each exert distinct requirements on imaging, motion management, and fractionation strategy that influence technology selection and staffing models. End users span ambulatory surgical centers, cancer treatment centers, and hospitals; ambulatory settings can be freestanding or hospital affiliated, cancer centers may operate as multispecialty hubs or standalone units, and hospitals vary between private and public ownership structures. Taken together, these intersecting segments drive differentiated investment profiles, staffing requirements, and service models that stakeholders must align to clinical priorities and operational realities

An incisive assessment of regional variation in infrastructure readiness, reimbursement frameworks, and strategic priorities shaping radiation therapy adoption worldwide

Regional dynamics continue to influence technology deployment, reimbursement environments, and strategic priorities across providers and vendors. The Americas exhibit diverse demand drivers, with some systems emphasizing advanced high-precision treatments and others focusing on expanding access through decentralized care sites; regulatory frameworks and reimbursement pathways vary across national and subnational jurisdictions, shaping procurement timelines and service models. Europe, Middle East & Africa comprise markets with heterogeneous infrastructure maturity, where regulatory convergence in some regions coexists with capacity constraints in others, prompting collaborative models and cross-border training initiatives to accelerate capability building.

Asia-Pacific presents a mixed landscape of rapid investment in advanced delivery platforms alongside ongoing efforts to expand basic radiotherapy capacity in underserved areas. Clinical practice patterns and referral networks in this region are evolving, with greater emphasis on building integrated cancer centers and exploiting telemedicine and remote planning to extend specialist expertise. Across all regions, interoperability standards, workforce training programs, and supply chain resilience are common priorities, even as local regulatory and reimbursement idiosyncrasies require tailored commercial and clinical engagement strategies.

Consequently, vendors and providers must calibrate go-to-market approaches to regional regulatory environments, infrastructure readiness, and clinical practice norms while investing in training and support ecosystems that facilitate sustainable adoption and quality assurance

Key competitive behaviors and strategic imperatives for firms in radiation oncology focusing on integrated solutions, clinical collaboration, and service-led differentiation

Company behavior in radiation oncology is characterized by strategic portfolio positioning, partnerships that bridge clinical and operational gaps, and investments in service models that extend device lifecycles. Leading manufacturers and technology providers emphasize integrated solutions that combine delivery platforms with planning and quality assurance software, while specialized therapy vendors focus on distinct niches such as particle delivery or stereotactic robotics. At the same time, professional service organizations and third-party maintenance firms have become critical in ensuring uptime and training, particularly for complex installations and multi-site networks.

Collaborative arrangements between vendors and health systems increasingly address lifecycle support, clinician training, and evidence generation. These alliances often take the form of clinical partnerships, research collaborations, and site-based training programs that help translate new capabilities into consistent clinical outcomes. Commercial strategies also reflect a shift toward outcome-oriented value propositions that emphasize throughput, reduced toxicity, or improved patient experience rather than hardware specifications alone.

To remain competitive, companies are expanding service footprints, deepening clinical evidence efforts, and strengthening regulatory and reimbursement expertise. Firms that combine robust technical support, demonstrable clinical benefit, and flexible procurement options will better support customers navigating capital constraints and evolving standards of care

Actionable strategic measures for leaders to align clinical evidence, supply resilience, and scalable service models that accelerate sustainable adoption

Industry leaders should adopt a multi-pronged approach that aligns clinical evidence, supply chain resilience, and operational scalability. First, prioritize investments in clinical validation programs and multidisciplinary trials that demonstrate comparative benefits for targeted indications, thereby strengthening the clinical case for adoption and facilitating payer discussions. Second, diversify supply chains through regional partnerships and dual-sourcing arrangements, and build inventory strategies that reduce exposure to trade policy shifts and logistical disruptions.

Third, accelerate software and workflow integration that improves planning efficiency and enables remote support, which in turn can scale expertise across decentralized sites. Fourth, develop comprehensive training programs and credentialing pathways for clinicians and medical physicists to ensure consistent quality across different delivery platforms and care settings. Fifth, engage proactively with payers and regulators to clarify reimbursement pathways and support value-based contracting where appropriate.

Finally, design flexible commercial models that include service bundles, modular financing, and outcome-linked elements to reduce procurement barriers for capital-intensive platforms. By implementing these measures in a coordinated manner, leaders can translate technological advances into sustained clinical impact while protecting operations from external shocks and regulatory uncertainty

A transparent description of the mixed-methods research approach that integrates clinical validation, operational observation, and policy analysis to ensure practical relevance

The research synthesis combines primary qualitative inputs and rigorous secondary analysis to ensure findings are grounded in clinical practice and operational realities. Primary methods included structured interviews with clinical leaders, medical physicists, and procurement executives, supplemented by site visits and direct observation of workflows in diverse treatment settings. These engagements provided insight into real-world scheduling constraints, staffing models, and the operational impact of new delivery technologies.

Secondary research encompassed peer-reviewed clinical literature, professional society guidelines, regulatory documentation, and device technical specifications to validate clinical claims and to map technological capabilities. The methodology also integrated analysis of service and maintenance models, reimbursement policy documents, and public capital procurement records to understand acquisition and lifecycle support dynamics. Cross-validation steps included triangulation of interview findings with published clinical outcomes and expert panels to resolve divergent perspectives.

Quality assurance procedures included transparent documentation of sources, clear statements of evidence strength, and review by independent clinical advisors. The result is a synthesis that prioritizes actionable insight and clinical relevance while providing clarity on the underlying evidence base and methodological limitations

A concise synthesis highlighting the convergent forces in clinical innovation, operational preparedness, and policy resilience that will determine lasting adoption

The cumulative analysis underscores that radiation oncology is evolving along multiple, convergent vectors: precision delivery technologies, advanced software ecosystems, decentralized care settings, and heightened supply chain scrutiny. These dynamics create both the opportunity to improve clinical outcomes and the obligation to manage operational complexity through evidence generation, workforce development, and resilient procurement practices. Clinical teams and administrators must therefore adopt integrated strategies that pair technological adoption with robust training and service models to sustain high-quality care across diverse sites.

Equally important is the recognition that external policy factors and trade dynamics influence more than procurement costs; they shape deployment timelines, vendor selection, and the nature of service partnerships. To navigate this environment, stakeholders should emphasize adaptable contracting, regional partnerships, and investment in remote support capabilities. When combined with focused clinical validation and payer engagement, these measures will help translate innovation into reliable improvements in patient care.

In sum, the path forward requires coordinated action across clinical, operational, and commercial domains to ensure that technological advances fulfill their promise in routine practice and that care delivery remains resilient in the face of policy and supply chain headwinds

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiation Oncology Market, by Technology

  • 8.1. Brachytherapy
    • 8.1.1. High Dose Rate
    • 8.1.2. Low Dose Rate
  • 8.2. Intensity Modulated Radiation Therapy
    • 8.2.1. Step And Shoot Imrt
    • 8.2.2. Volumetric Modulated Arc Therapy
  • 8.3. Proton Therapy
    • 8.3.1. Passive Scattering
    • 8.3.2. Pencil Beam Scanning
  • 8.4. Stereotactic Body Radiotherapy
    • 8.4.1. Cyberknife
    • 8.4.2. Linac Based
  • 8.5. Three Dimensional Conformal Radiation Therapy

9. Radiation Oncology Market, by Component

  • 9.1. Hardware
  • 9.2. Services
  • 9.3. Software

10. Radiation Oncology Market, by Delivery Mode

  • 10.1. External Beam
    • 10.1.1. Rotational Beam
    • 10.1.2. Stationary Beam
  • 10.2. Intraoperative
    • 10.2.1. Minimally Invasive
    • 10.2.2. Open Surgery

11. Radiation Oncology Market, by Application

  • 11.1. Breast Cancer
  • 11.2. Head And Neck Cancer
  • 11.3. Lung Cancer
  • 11.4. Prostate Cancer

12. Radiation Oncology Market, by End User

  • 12.1. Ambulatory Surgical Centers
    • 12.1.1. Freestanding
    • 12.1.2. Hospital Affiliated
  • 12.2. Cancer Treatment Centers
    • 12.2.1. Multispecialty
    • 12.2.2. Standalone
  • 12.3. Hospitals
    • 12.3.1. Private
    • 12.3.2. Public

13. Radiation Oncology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radiation Oncology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radiation Oncology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Radiation Oncology Market

17. China Radiation Oncology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Accuray Incorporated
  • 18.6. Bayer AG
  • 18.7. Best Medical International, Inc.
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Elekta AB
  • 18.10. Hitachi, Ltd.
  • 18.11. Ion Beam Applications SA
  • 18.12. Isoray, Inc.
  • 18.13. Mevion Medical Systems, Inc.
  • 18.14. Novartis AG
  • 18.15. Panacea Medical Technologies Pvt. Ltd.
  • 18.16. RefleXion Medical, Inc.
  • 18.17. Siemens Healthineers AG
  • 18.18. Varian Medical Systems, Inc.
  • 18.19. ViewRay, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIATION ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIATION ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIATION ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RADIATION ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RADIATION ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIATION ONCOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HIGH DOSE RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HIGH DOSE RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HIGH DOSE RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LOW DOSE RATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LOW DOSE RATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LOW DOSE RATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEP AND SHOOT IMRT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEP AND SHOOT IMRT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEP AND SHOOT IMRT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY VOLUMETRIC MODULATED ARC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PASSIVE SCATTERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PASSIVE SCATTERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PASSIVE SCATTERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PENCIL BEAM SCANNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PENCIL BEAM SCANNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PENCIL BEAM SCANNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CYBERKNIFE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CYBERKNIFE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CYBERKNIFE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LINAC BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LINAC BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LINAC BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY THREE DIMENSIONAL CONFORMAL RADIATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY THREE DIMENSIONAL CONFORMAL RADIATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY THREE DIMENSIONAL CONFORMAL RADIATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HARDWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HARDWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HARDWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY ROTATIONAL BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY ROTATIONAL BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY ROTATIONAL BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STATIONARY BEAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STATIONARY BEAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STATIONARY BEAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY FREESTANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY FREESTANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY FREESTANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITAL AFFILIATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITAL AFFILIATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITAL AFFILIATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MULTISPECIALTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MULTISPECIALTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY MULTISPECIALTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STANDALONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STANDALONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY STANDALONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL RADIATION ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 258. GCC RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. GCC RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. GCC RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. GCC RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 265. GCC RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 266. GCC RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 267. GCC RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 268. GCC RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. GCC RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 271. GCC RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. GCC RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 303. G7 RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. G7 RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. G7 RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 306. G7 RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 307. G7 RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 308. G7 RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. G7 RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 310. G7 RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 311. G7 RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 312. G7 RADIATION ONCOLOGY MARKET SIZE, BY INTRAOPERATIVE, 2018-2032 (USD MILLION)
  • TABLE 313. G7 RADIATION ONCOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. G7 RADIATION ONCOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. G7 RADIATION ONCOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, 2018-2032 (USD MILLION)
  • TABLE 316. G7 RADIATION ONCOLOGY MARKET SIZE, BY CANCER TREATMENT CENTERS, 2018-2032 (USD MILLION)
  • TABLE 317. G7 RADIATION ONCOLOGY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 318. NATO RADIATION ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 319. NATO RADIATION ONCOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 320. NATO RADIATION ONCOLOGY MARKET SIZE, BY BRACHYTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 321. NATO RADIATION ONCOLOGY MARKET SIZE, BY INTENSITY MODULATED RADIATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 322. NATO RADIATION ONCOLOGY MARKET SIZE, BY PROTON THERAPY, 2018-2032 (USD MILLION)
  • TABLE 323. NATO RADIATION ONCOLOGY MARKET SIZE, BY STEREOTACTIC BODY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 324. NATO RADIATION ONCOLOGY MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 325. NATO RADIATION ONCOLOGY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 326. NATO RADIATION ONCOLOGY MARKET SIZE, BY EXTERNAL BEAM, 2018-2032 (USD MILLION)
  • TABLE 327. NATO RADIATION ONCOLOGY MARKET SIZ